EXCENEL RTU FLUID VETERINARY

البلد: إسرائيل

اللغة: الإنجليزية

المصدر: Ministry of Health

اشتر الآن

العنصر النشط:

CEFTIOFUR HYDROCHLORIDE

متاح من:

ZOETIS ISRAEL HOLDING B.V., ISRAEL

الشكل الصيدلاني:

SUSPENSION FOR INJECTION

تركيب:

CEFTIOFUR HYDROCHLORIDE 50 MG / 1 ML

طريقة التعاطي:

I.M, S.C

نوع الوصفة الطبية :

Required

المصنعة من قبل:

ZOETIS BELGIUM S.A.

الخصائص العلاجية:

Infections associated with bacteria sensitive to ceftiofur: * In pigs : For the treatment of bacterial respiratory disease associated with Pasteurella multocida Actinobacillus pleuropneumoniae and Streptococcus suis. *In cattle : For the treatment of bacterial respiratory disease associated with Mannheimia haemolytica (former pasteurella haemolytica) Pasteurella multocida and Histophilus somni (fomer Haemophilus somnus). For the treatment of acute interdigital necrobacillosis ( panaritium foot rot) associated with Fusobacterium necrophorum and Bacteroides melaninogenicus (Porphyromonas asaccharolytica). For treatment of the bacterial coponent of acute post-partum (puerperal) metritis within 10 days after calving associated with Escherichia coli Arcanobacterium pyogenes and Fusobacteriu necrophorum sensitive to ceftiofur where treatment with another antimicrobial agent has failed.

تاريخ الترخيص:

2022-01-31

نشرة المعلومات

                                CONSUMER PACKAGE INSERT FOR
A VETERINARY PREPARATION
The medicine is dispensed with a veterinarian’s prescription only
For animal use only
1. NAME, FORM AND STRENGTH OF THE VETERINARY
MEDICINE
Excenel RTU Fluid Veterinary suspension for intramuscular and
subcutaneous injection
2. ACTIVE INGREDIENT
Ceftiofur (as hydrochloride) 50 mg/
ml
The list of inactive ingredients is in section 13.
3. WHAT IS THE MEDICINE INTENDED FOR?
For treatment of infections associated with bacteria sensitive to
ceftiofur.
In pigs
For the treatment of bacterial respiratory disease associated with:
_Pasteurella multocida_, _ Actinobacillus pleuropneumoniae_ and
_Streptococcus suis_.
In cattle
For the treatment of bacterial respiratory disease associated with:
_Mannheimia haemolytica_ (former _Pasteurella haemolytica_),
_Pasteurella _
_multocida_ and _Histophilus somni_ (former _Haemophilus somnus_).
For the treatment of acute interdigital necrobacillosis (Panaritium
Foot
Rot) associated with: _Fusobacterium necrophorum_ and _Bacteroides _
_melaninogenicus_ (_Porphyromonas asaccharolytica_).
For treatment of the bacterial component of acute post-partum
(puerperal) metritis within 10 days after calving associated with:
_Arcanobacterium pyogenes, Escherichia coli _ and _ Fusobacteriu _
_necrophorum_ sensitive to ceftiofur where treatment with another
antimicrobial agent has failed.
Therapeutic group:
Antibacterials for systemic use. Third-generation cephalosporins.
4. CONTRAINDICATIONS
Do not use if the animal has a known hypersensitivity to ceftiofur and
other beta-lactam antibiotics.
Do not inject intravenously.
Do not use in case of resistance to cephalosporins or to other beta-
lactam antibiotics.
Do not use in poultry (including egg laying poultry), to prevent
spread
of variants resistant to the preparation to humans.
5. SIDE EFFECTS
Hypersensitivity reactions unrelated to the dosage can occur. Allergic
reactions (e.g., skin reactions or anaphylaxis) have very rarely been
reported (fewer than one in 10,000 animals, including isolated

                                
                                اقرأ الوثيقة كاملة
                                
                            

مستندات بلغات أخرى

نشرة المعلومات نشرة المعلومات العربية 25-12-2018
نشرة المعلومات نشرة المعلومات العبرية 25-12-2018

تنبيهات البحث المتعلقة بهذا المنتج

عرض محفوظات المستندات